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Abstract: Myoma uteri related to the interaction between genes, hormones, growth 
factors, cytokines, and environment. Myomas are not found before menarche, 
whereas after menopause only 10% of myomas grow. The development of uterine 
myoma depends on estrogen. CYP1A1 is one of three members of the CYP1 family 
that is involved in the metabolism of a large number of xenobiotics. The purpose of 
this study was to analyze the relationship between the CYP1A1 gene polymorphism 
(Ile462Val) and the incidence of uterine myoma in ethnic Malays in South 
Sumatera. This research is an observational study with a case control design. The 
blood samples taken from 35 cases and 35 controls. The data was analyzed using 
the Chi-square test. The results indicate that there is a significant relationship 
between the use of contraceptives on the incidence of uterine myoma. There is a 
significant relationship between the CYP1A1 gene polymorphism (Ile462Val) and 
the CYP1A1 allele (Ile462Val) with uterine myoma. It is concluded that there is a 
polymorphism relationship between the genotype and allele of the CYP1A1 gene 
(Ile462Val) and the incidence of uterine myoma in ethnic Malays in South 
Sumatera. 
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Abstrak: Mioma uteri adalah penyakit yang berkaitan dengan interaksi antara beberapa 
gen, hormon, faktor pertumbuhan, sitokin, dan lingkungan. Mioma  tidak  ditemukan 
sebelum terjadinya menarkhe, sedangkan setelah menopause hanya 10% mioma yang  
tumbuh. Perkembangan mioma  uteri bergantung pada estrogen. CYP1A1 merupakan satu 
dari tiga anggota famili CYP1 yang berperan serta pada metabolisme sejumlah besar 
xenobiotic.  Tujuan penelitian ini untuk menganalisis hubungan antara polimorfisme gen 
CYP1A1 (Ile462Val) dengan kejadian mioma uteri pada etnis Melayu di Sumatera 
Selatan. Penelitian ini merupakan penelitian analitik observasional dengan desain case 
control. Sampel penelitian menggunakan sampel darah yang diambil pada 70 sampel yang 
terdiri dari 35 kasus dan 35 kontrol. Distribusi frekuensi hubungan polimorfisme dan 
sosiodemografi pada mioma uteri  antara kasus dan kontrol dianalisis menggunakan uji Chi-
square. Hasil penelitian ini menunjukkan bahwa ada hubungan yang bermakna pemakaian 
alat kontrasepsi terhadap kejadian mioma uteri, ada hubungan bermakna antara 
polimorfisme gen CYP1A1 (Ile462Val) dan alel CYP1A1 (Ile462Val) dengan mioma uteri. 
Disimpulkan bahwa terdapat hubungan polimorfisme antara genotipe maupun alel gen 
CYP1A1 (Ile462Val) dengan kejadian Mioma uteri pada etnis Melayu di Sumatera 
Selatan. 
Kata Kunci: Mioma uteri, Polimorfisme, Gen CYP1A1, alel CYP1A1, Etnis Melayu 
INTRODUCTION 
 
Uterine myomas are benign tumors in the 
uterine muscle or myometrium that interact with 
several genes, hormones, growth factors, 
cytokines, and the environment.1 Myoma incidence 
is estimated at 20% -40% in the world. This disease 
does not occur before menarche, and after 
menopause it is estimated that 10% of this disease is 




30% in women over 35 years. In Indonesia, the 
incidence of uterine myomas is happened to 20-30% 
women over 35 years. 3 Uterine myomas are often 
asymptomatic, but can cause abdominal 
discomfort, uterine bleeding, pelvic pain, and 
infertility. 4 These tumors affect 30% of women of 
reproductive age.5 Uterine myomas as common 
benign neoplasms of the uterus involve nearly 30-
40% of women childbearing age. 6  
Myoma uteri originates from the smooth 
muscle of the uterus and develops from stimulation 
of the hormone estrogen. The development of 
uterine myomas depends on estrogen.4 The number 
of estrogen receptors in the myoma tissue is above 
when compared to the muscle tissue in the 
surrounding uterus so that this disease grows very 
rapidly in pregnancy or enlarges at reproductive age 
and decreases in size after menopause or post 
menopause.7 
The results show that the growth and 
development of uterine myomas is depended on 
estrogen.8 During pregnancy, uterine myomas can 
cause a number of problems such as bleeding in the 
first trimester, placental displacement, preterm 
labor, and miscarriage.9 Uterine myomas are a big 
problem, but effective therapy has not been 
obtained, because there is little information about 
the etiology of myoma itself. This disease does not 
often cause mortality, but morbidity that can result 
in abdominal pain, abnormal bleeding, and possibly 
infertility.10  
The cause of uterine myoma is not known 
certainly, but the effects of hormonal, genetic, and 
growth factors on myoma growth are known. 
Several theories about meioma uteri are related to 
the decrease of fertility. The relationship between 
myoma and low fertility has been reported by two 
observational surveys.11 It has been shown that 27- 
40% of those infected with this disease are infertile. 
The formation of these tumors comes from somatic 
changes in the muscle tissue cells of the uterus. 
Somatic changes are prone to partial and complete 
chromosomal mutations. Chromosomal aberrations 
can be found in 23-50% of the results of this disease 
examination and the overall result (36.6%) is found 
on chromosome 7 (del (7) (q 21) / q 21 q 32) .12 
Muscle cells contribute to uterine myoma. 
There are two estrogen receptors in uterine 
myomas, namely ER-alpha and ER-beta.13 The 
CYP450 cytochrome system is a group of enzymes 
involved in the biosynthesis of steroid hormones 
and the activation of metabolic carcinogens. CYPIA1 
is a CYP450 enzyme, the main enzyme involved in 
the catabolism of estrogen. CYP1A1 is one of three 
members of the CYP1 family that is involved in the 
metabolism of a large number of xenobiotics.  
The polymorphism of the CYP1A1 gene can be 
found by analyzing PCR-RFLP (Polymerase Chain 
Reaction Restriction Fragment Length 
Polymorphism), so the change in location of G to T 
is known. Ye et al. (2018) 1 proved that there is a risk 
relationship between uterine leiomyoma and 
CYP1A1 gene polymorphism, this is the same as the 
study results obtained by Herr, et al (2006). 6 who 
stated that the polymorphism of the cytochrome 
P450 1A1 gene in uterine leiomyomas has nothing to 
do with the polymorphism of the CYP1A1 gene. 
Based on the previous research, it is known that 
there is a relationship between GEN CYP1A1 
(Ile462Val) and leiomyoma uteri, therefore it is 
necessary to study the relationship between CYP1A1 
gene polymorphism (Ile462Val) and uterine myoma 
in Malays ethnicity in Indonesia, especially in South 
Sumatera, which is Indonesia's occupied territory. 
the majority ethnic Malay descent. 
 
MATERIALS AND METHOD 
 
This analytic observational study used a case 
control design. This analytical study explored risk 
factors that are studied with a retrospective 
approach. This study was approved by the ethics 
committee of the Medical Faculty of Sriwijaya 
University and all respondents had signed an 
informed consent. 
 Patients who seek treatment at the 
Obstetrics and Gynecology polyclinic RS. Dr. 
Mohammad Hoesin in Palembang and diagnosed 
with uterine myoma was the population of this 
analytic study. Samples were taken of 35 cases and 
35 controls who met the inclusion and exclusion 
criteria. The inclusion criteria for the case group 
were classified as Malay ethnicity women 
diagnosed with uterine myoma as evidenced by 
ultrasound examination and had the results of an 
anatomical pathology examination, while in the 
control group, Malay ethnic women who were not 
diagnosed with this disease could be proven by 
ultrasound. The case and control groups were 
willing to have blood drawn, signed an informed 
consent and were 16 to 50 years old, while the 
exclusion criteria were women with gynecological 
neoplasm.  
 Sample, in the form of 3 ml of blood from 
patients and healthy volunteers, were collected in a 
tube containing EDTA as an anticoagulant. Blood 
from each respondent in this study was stored at 
20˚C until DNA extraction was performed. DNA 
extraction using a DNA extraction kit (Promega). 
 
94 |  
 
Vol 20 No 2 
July 2020 
The genotype of the CYP1A1 gene (Ile462Val) was 
determined by the Polymerase Chain Reaction 
Restriction Fragmenth Length Polymorphism (PCR-
RFLP) method, using forward primer: 5'-
CTGTCTCCCTCTGGTTACAGGAAGC-3 'and reverse 
primer: 5'-TTCCACCCGTTGCAGCAGGATAGCC-3' 
 The Polymerase Chain Reaction process was 
carried out in the I - cycler (Biorad) machine. 
Basically, DNA amplification using the Polymerase 
Chain Reaction machine is a bireksional repetitive in 
vitro DNA synthesis through the extension of a pair 
of oligonucleotide primers that have been designed 
through the nucleotide sequences of the two 
amplified DNA chains. 
 The DNA synthesis process that has been 
carried out in 35 cycles runs in three stages of 
reactions that occur at different temperatures, 
namely the denaturation reaction at 94ºC for 5 
minutes, the annealing reaction at 64.7ºC for 30 
seconds, and the extension reaction at 72ºC for 30 
seconds. Before that, the pre-denaturation process 
was carried out for 5 minutes at a temperature of 
94ºC. This denaturation reaction functions to 
separate the DNA double chain into a single DNA 
chain. In this annealing reaction, the two primers 
attach to the two single DNA chains. After that in 
the extension reaction, the additional extension 
lasted 72 ºC for 10 minutes. Polymerase Chain 
Reaction products are electrophoresed on 2% 
agarose gel to produce ethidium bromide. 
 Analysis of the frequency distribution data 
of the relationship between polymorphism and 
sociodemographic on uterine myoma between 
cases and controls using the Chi-square test to 
determine the odds ratio (OR) with a confidence 





Sociodemographic characteristics both cases 
and controls are shown in Table 1. The results of this 
study indicate that uterine myoma was found more 
frequently in women over 35 years in the myoma 
uterine case group, as many as 25 respondents 
(71.4%). Based on the Chi Square test, it shows that 
there is no significant relationship between the age 
of the respondent and the incidence of uterine 
myoma (ρ> 0.05). 
Besides, the respondents whose age of 
menarche less than 10 years in the case group were 
very few, namely 1 person (2.9%) and none in the 
control group (0.0%). Respondents whose 
menarche age> 10 years in the case group were 34 
people (97.1%) and in the control group, 35 people 
(100%). Based on the Chi Square test, there was no 
significant relationship between the age of 
menarche and the incidence of uterine myoma (ρ> 
0.05). 
 
There were 19 respondents (54.3%) who gave 
birth less than 2 times in the case group and 15 
(42.9%) in the control group. Respondents who 
gave birth more than 2 times in the case group were 
16 people (45.7%) and in the control group were 20 
people (57.1%). Based on the Chi Square test, there 
was no significant relationship between the number 
of births and the incidence of uterine myoma (ρ> 
0.05). 
 The number of respondents who did not use 
contraception in the case group was 26 people 
(74.3%) and 12 people in the control group (34.3%), 
while 23 respondents in the control group used 
contraception (65 , 7%) and respondents who did 
not use contraception were 12 people (34.3%). 
Based on the Chi Square test, it shows that there is 
a significant relationship between the use of 
contraceptives to the incidence of uterine myoma 
(ρ <0.05). 
 In this study, the respondents with non-
smoking partners in the case group were 14 and in 
the control group 14 people (40.0%), while 
respondents with smoking partners were 21 (60.0%) 
and in the case group and in the control group. 
Based on the results of the Chi Square test, it 
showed that there was no significant relationship 
between partners who smoked and the incidence 
of uterine myoma (ρ> 0.05). 
 In the family history data on the incidence of 
uterine myoma in the case group were 5 
respondents (14.3%) and the control group was 3 
(8.6%), while there was no family history of the 
incidence of uterine myoma in the case group as 
many as 30 respondents (85, 7%) and the control 
group was 32 (91.4%). Based on the results of the 
Chi Square test, it was found that there was no 
significant relationship between family history and 
the incidence of uterine myoma (p> 0.05). 
 The measurements of the genetic frequency 
of respondents with uterine myomas with wild type 
(TT) characteristics, heterozygous mutants (TC) and 
homozygous mutants (CC) are shown in Table 2. In 
the case group, uterine myomas with wild type 
characteristics were the most with 22 people 
(62.9%), followed by heterozygous mutants (TC) by 
11 people (31.4%) and homozygous mutants by 2 
people (5.7%). In the control group, uterine myoma 
with wild type characteristics was the most with 12 
people (34.2%), followed by heterozygous mutants 
(TC) by 15 people (42.9%) and homozygous mutants 






Table 1. Frequency Distribution and the Relationship of the Characteristics of Research Subjects to the Incidence of 
Uterine Myoma 
Characteristics 






% n (%) P  OR (95% CI) 
Age        
<35 years 10 28.6 18 51.4 28 (40.0) 0,088 2.647 (0985-7.113) 
>35 years 25 71.4 17 48.6 42 (60.0) 
Menarche        
<10 years 1 2.9 0 0 1 (1.4) 1,000 2.029 (1.597-2.578) 
>10 years 34 97.1 35 100 69 (98.6) 
Parity        
<2 19 54.3 15 42.9 34 (48.6) 0,473 0.632 (0.246-1.623) 
>2 16 45.7 20 57.1 36 (51.4) 
Contraception        
No  26 74.3 12 34.3 38 (54.3) 0,002* 0.181 (0.064-0.506) 
Yes 9 25.7 23 65.7 32 (45.7) 
Smoking        
No 14 40.0 14 40.0 28 (40.0) 1,000 1.000 (0.384-2.602) 
Yes 21 60.0 21 60.0 42 (60.0) 
Family History        
No 30 85.7 32 91.4 62 (88.6) 0,707 1.778 (0.391-8.092) 
Yes 5 14.3 3 8.6 8 (11.4) 
Note:*) based on χ2 Chi-Square test there is significant relation (p<0,05) 
 
Table 2. Frequency distribution of the CYP1A1 (Ile462Val) 
genotype on the incidence of uterine myoma 
Characteristics 















2 5.7 8 22.9 10 
(14.3) 
Total 35 100 35 100 70 
(100) 
Note: *) based on  χ2 test 
 
Table 3 Frequency distribution of the CYP1A1 Ile462Val 
gene allele in cases and controls of uterine myoma 
Allel 
Uterin Myoma Total 
Case % Control % n(%) 
C 15 21.4 31 44.3 46 (32.9) 
T 55 78.6 39 55.7 94 (67.1) 
Total 70 0% 70 0% 140 (100) 
 
 
Table 4. Analysis of the Relationship between CYP1A1 
Genotype Polymorphisms (Ile462Val) and the 
incidence of uterine myoma. 
Geno 
type 
Uterin Myoma  Total 
Cs % Ctl % P  OR 95% CI 






TC 11 31.40 15 42.9    
CC 2 5.70 8 22.90    
Total 35 100 35 100    
Note: *= significant (p<0.05) based on χ2 test 
 
 The measurement of the allele frequency 
distribution, based on Table 3. T allele in the case 
group amounted to 55 (78.6%) and 39 controls 
(5.7%), the C allele in the case group amounted to 15 
(21.4%) and control 31 (44.3%). 
 Based on the Table 4, the analysis of the 
relationship between the CYP1A1 gene 
polymorphism (Ile462Val) and the incidence of 
uterine myoma showed that the TT genotype in the 
case group was 22 (62.9%) and 12 in control (34.3%), 
while the TC genotype in the case group amounted 
to 11 (31.4%) and control amounted to 15 (42.9%). 
Genotype CC in case group 2 people (5.7%) and 
control 8 (22.9%). The highest number was found in 
the TT genotype in the group of cases of uterine 
myoma. Based on the results of statistical analysis 
using the Chi-Square test, it was found that there 
was a significant relationship between the CYP1A1 




Table 5. Analysis of the Correlation of CYP1A1 
(Ile462Val) allele polymorphisms to the 
incidence of uterine myoma. 
Geno 
type 
Uterin Myoma   










C 15  21.
4 
31 44.3    
Total 70 100 70 100    
Note: *= significant (p<0,05) based on χ2 test 
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 The analysis of the relationship between the 
polymorphism of the CYP1A1 gene allele (Ile462Val) 
on the incidence of uterine myoma found that the T 
allele in the case group was 55 (78.6%) and the 
control was 39 (55.7%), while the C allele in the case 
group amounted to 15 (21.4%) and control 
amounted to 31 (44.3%). A higher number was 
found in the T allele in the case of uterine myoma 
than the C allele as well as in the control group. The 
results of statistical analysis using the Chi-Square 
test to see the relationship between the CYP1A1 
allele (Ile462Val) and the incidence of uterine 
myoma showed a significant relationship between 
the CYP1A1 allele (Ile462Val) on the incidence of 
uterine myoma with a value of ρ = 0.007 (OR 0.343; 




 CYP1A1 is one of three members of the CYP1 
family that is involved in the metabolism of a large 
number of xenobiotics. CYP1A1 is one of the major 
cytochromes P450 enzymes, examined extensively 
for its ability to activate compounds that are 
carcinogenic. CYP1A1 gene polymorphisms, 
contribute to an increase in the predisposition that 
causes uterine myoma. CYP1A1 is one of the CYP450 
enzymes involved in the catabolism of estrogen. 
 Myoma uteri can be found more in the 
population of women aged over 35 years in the 
myoma uterine case group. This is in accordance 
with the results of Ye et al (2008), 1 who states that 
women over 35 years have a high risk in 
experiencing uterine myoma. Likewise, with the 
results of research conducted by Octaviana and 
Pranajaya (2014) 14 stated that the older a person is, 
the risk of developing myoma uteri increases. 
 Uterine myoma more often occurs at the 
above 10 years in the myoma uterine case group. 
The results of this study are supported by research 
which shows that menarche over 10 years of age 
have a risk of uterine myoma. The age of menarche 
varies from person to person, especially the age of 
menarche which is influenced by genetic and 
external factors, such as stress, diet, chronic 
disease, and lifestyle. 
 More uterine myomas were found at parity 
<2 in the uterine myoma case group. Nullipara, this 
incident is easier to find because the secretion of 
estrogen in pregnant women is completely 
different from the secretion by the ovaries in non-
pregnant women. In pregnant women, almost all of 
the estrogen produced is estriol. Estriol is an 
estrogen which is relatively weaker than the 
estradiol secreted against the ovaries. 
 Uterine myomas are more common in 
women who do not use contraception. The results 
of this study are not in accordance with the 
research of Fahrunniza (2014) 15 who stated that 
one of the triggers for uterine myoma is the use of 
the hormones estrogen and progesterone obtained 
through hormonal contraceptives. 
 The results of this study indicate that the 
respondents whose husbands smoke showed no 
relationship with cases of uterine myoma. This is in 
accordance with the results of research conducted 
by Wise (2016) ,16 who stated that there is no 
change in the risk of African and American women 
smoking. Although in theory, smoking can increase 
myoma risk because it can reduce estrogen levels in 
the body which results in the growth of uterine 
myomas. 
 The results showed that there was no 
significant relationship between family history and 
the incidence of uterine myoma. The results of this 
study are not in accordance with the research of 
Nida (2014) 15 who states that there is a link between 
family history and the incidence of uterine myoma. 
According to the theory, women who have a 
hereditary history of uterine myoma are 2.5 times 
more likely to experience myoma than women 
without this lineage. 
 The identification of the CYP1A1 (Ile462Val) 
gene polymorphism in this uterine myoma patient is 
in accordance with a study conducted by Hsieh 
(2004) which showed that there were genotypes 
between wild type, heterozygous and homozygous 
mutants in samples of Chinese women. 
Polymorphism of the CYP1A1 gene (Ile462Val) may 
be a risk factor for uterine myoma in Iranian 
women. 
 Genotype polymorphisms and the CYP1A1 
gene allele (Ile462Val) are associated with the 
incidence of uterine myoma against ethnic Malays 
in South Sumatera. The contribution of CYP1A1 in 
the development of uterine myoma varies between 
each population because it is influenced by many 
things including the presence of the hormone 
estrogen, and the interaction of genes with 
environmental factors.18 Polymorphisms in the 
CYP1A1 gene (Ile462Val) are a risk factor for uterine 
myoma in Chinese, Iranian, German women due to 




 There is a polymorphism relationship 
between the genotype and allele of the CYP1A1 
gene (Ile462Val) and the incidence of uterine 
myoma in ethnic Malays in South Sumatera. It is 




polymorphism of the CYP1A1 gene (Ile462Val) 
against the incidence of uterine myoma that occurs 
in other populations in Indonesia, so that it can be 
compared to the function of the CYP1A1 gene 
polymorphism (Ile462Val) on the incidence of 
uterine myoma and it is necessary to add incubation 
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